Pre Diagnostics

Pre Diagnostics AS Non-Confidential Company Presentation

Vision

A world where early detection of neurodegenerative disease enables treatment before it’s too late

“We need to detect and diagnose Alzheimer’s earlier.”

Bill Gates

The problem with diagnosing Alzheimer’s Disease

“A more reliable, affordable, and accessible diagnostic—such as a blood test—would make it easier to see how Alzheimer’s progresses and track how effective new drugs are.”

The PreADx solution – a disruptive blood test

A **non-invasive** test to diagnose and monitor in early stages of Alzheimer's

Intracellular test approach in monocytes, provides more disease relevant information

The **dynamic** test detects AB peptides - the hallmark of underlying disease pathology for AD – in blood cells

Patented concept for successful **drug development** for Big Pharma and **early diagnosis** for patients - before irreversible brain damage occurs

Market opportunity

Confirmed market traction in a large and growing market

Demographic growth driver



Market Segments

BIOMAKER

MSD · Lilly · Takeda · Biogen · Roche · Eisai

IVD INDUSTRY

Roche · ThermoFisher SCIENTIFIC · SIEMENS · Abbott

€ 300BN Annual EU public costs

€ 350BN NPV Opportunity

Product development

EU-funding for a CE-regulated diagnostic test, with focus on two key elements

Blood sampling and monocyte isolation





Anti-complex sandwich immunoassay



Business Model

Lean collaboration-based model leveraging key IP assets

R&D Suppliers and Collaborators

Akershus University Hospital

Quanterix

FÜRST MEDISINSK LABORATORIUM

bioventix

ThermoFisher SCIENTIFIC

shareLAB

Business Model

Global exclusive license to IP covering several neurodegenerative diseases beyond AD secured

Lean operation with strong network of global development partners

Commercialization through out-licensing: Sale and marketing of PreADx by partner networks in different segments and markets

Platform technology that can be developed for other indications

Go-to-market strategy

Stepwise entry into three attractive market segments

Biomarker

- Direct sales model with sale of RuO product to pharma/biotech customers as first step in commercialization, through own lab or collaboration with regional labs
- Building scientific documentation as preparation for IVD market entry

IVD

- Out-licensing of IP to global/regional IVD players for commercialization of test in diagnostic markets
- Alternative models, incl distribution model, also under consideration

OTC

- OTC/Nutraceutical market as attractive long-term opportunity to be explored with industry partners with complementary assets
- Multiple potential business models

Product Development Timeline



Outlicensing

Biomarker Selection | Feasilbility Studies | Prototype Assay | Analytical Validation | Clinical Validation | Regulatory Approval | Clinical Utility

Key development milestones - description

PoC A

Analytical Lock

Immunoassay is technically optimized and detects the Ab peptides at the x-34 cutpoint

PoC B

Clinical Relevance

Test to be run on smaller number of blood samples (less than 100 samples) and statisticially significant result between healthy controls and AD patients

PoC C

Clinical Validation

Test to be run on 4 cohorts of 50 well-characterized samples demonstrating biological relevance

CE IVD

CE IVD Validation

Full regulatory validation package for CE marking submitted, validation plan and documentation requirements depend on intended use claim

The team

50+ years of international biotech, diagnostics and pharma industry experience

Erik Christensen

CO-FOUNDER, CMO

Håkon Sæterøy

CO-FOUNDER, CEO

Charlotte Berg-Svendsen

CCO

Funding

Horizon 2020 EU grant = significant milestone

Funding status YTD

Grants		Equity raised
€ 1,5M	2014-2019	€ 1,8M
€ 2,5M	2019-2021	€ 1,1M

The Research Council of Norway

Innovation Norway

HORIZON 2020

Future funding for AD and other indications

- Commercialization in the EU, incl. service lab for RuO product
- US market access, incl. trials for FDA approval (with partner)
- Pipeline development

European Commission

Funding up to CE-launch in the EU in 2021 in place

Top 20 shareholders